Lawrence Carter, USA

Clinical (1)
PB2.1: Baseline characteristics for INFRONT-3: A Phase 3 double-blind, placebo-controlled 96-week study evaluating latozinemab in FTD-GRN
Date: 20 Sep 2024Time: 09:30 - 09:34 CET

Home › Lawrence Carter, USA